Figures computed from official regulatory filings — .
Analysttarget 8.12 USD (+10%)
Ownershipinsiders 2.18% · institutions 52.3% · short 6.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Atai Beckley N.V. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments. The company develops rapid-acting and durable therapies for conditions with limited treatment options. Its pipeline includes BPL-003 (mebufotenin benzoate), an intranasal formulation in Phase 2 and 3 clinical studies for treatment-resistant depression and alcohol use disorder; ELE-101, a serotonergic psychedelic for major depressive disorder; and RL-007, an orally bioavailable pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia. The company's pipeline also comprises VLS-01, an oral transmucosal film formulation of N, N-Dimethyltryptamine in Phase 2 clinical study for treatment-resistant depression; EMP-01, an oral formulation of the R-enantiomer of 3,4-methylenedioxy-methamphetamine in Phase 2 clinical study for social anxiety disorder; and EGX-A and EGX-B, non-hallucinogenic 5-HT2A receptor agonists for treatment-resistant depression. Additionally, it offers COMP360, a psilocybin therapy; and GRX-917, a treatment for anxiety, depression, and various neurological disorders. The company has additional operations in Germany and Canada. AtaiBeckley Inc. was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York. AtaiBeckley Inc. operates as a subsidiary of Eli Lilly and Company.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
30 buys9 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Feilding-Mellen Cosmo | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Feilding-Mellen Cosmo | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Braunstein Scott | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Feilding-Mellen Cosmo | Award | n/a (No price was disclosed in the filing) | SEC |
| Feilding-Mellen Cosmo | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| HERSHBERG ROBERT | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| HERSHBERG ROBERT | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| HERSHBERG ROBERT | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Feilding-Mellen Cosmo | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| HERSHBERG ROBERT | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Barrett Christopher Ryan Cave | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Apeiron Investment Group Ltd.track record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Apeiron Investment Group Ltd.track record | Other | n/a (No price was disclosed in the filing) | SEC |
| Apeiron Investment Group Ltd.track record | Buy | $19M | conv 47Unusual size | SEC |
| Rao Srinivas | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Rao Srinivas | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| JOHNSON SABRINA MARTUCCI | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kalali Amir H | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hoffman John Francis | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Angermayer Christiantrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Braunstein Scott | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fischer Laurenttrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Smiley Andrea Heslin | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Angermayer Christiantrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Kirpekar Sahil | Sell | $65.6K | SEC |